NO995770L - Salts of aromatic sulfonic acids - Google Patents

Salts of aromatic sulfonic acids

Info

Publication number
NO995770L
NO995770L NO995770A NO995770A NO995770L NO 995770 L NO995770 L NO 995770L NO 995770 A NO995770 A NO 995770A NO 995770 A NO995770 A NO 995770A NO 995770 L NO995770 L NO 995770L
Authority
NO
Norway
Prior art keywords
aromatic sulfonic
salts
sulfonic acids
salt
oxepino
Prior art date
Application number
NO995770A
Other languages
Norwegian (no)
Other versions
NO995770D0 (en
Inventor
Gerardus Johannes Heeres
Franciscus Hermanus Anto Bakel
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO995770L publication Critical patent/NO995770L/en
Publication of NO995770D0 publication Critical patent/NO995770D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen er et salt av det CNS-depressante trans-5-klor-2,3,3a,12b- tetrahydro-2-metyl-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol og et saltdannende middel, idet sistnevnte er en aromatisk sulfonsyre. Det beskrevne salt, fortrinnsvis benzylatet, har gunstige egenskaper. Således har det den nødvendige uløselig- het og krystallinitet til å være egnet for anvendelse i depot injeksjonspreparater.The invention is a salt of the CNS-depressant trans-5-chloro-2,3,3a, 12b-tetrahydro-2-methyl-1H-dibenz [2,3: 6,7] oxepino [4,5-c] pyrrole and a salt-forming agent, the latter being an aromatic sulfonic acid. The salt described, preferably the benzylate, has favorable properties. Thus, it has the necessary insolubility and crystallinity to be suitable for use in depot injection preparations.

NO995770A 1997-05-26 1999-11-25 Salts of aromatic sulfonic acids NO995770D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201596 1997-05-26
PCT/EP1998/003022 WO1998054186A1 (en) 1997-05-26 1998-05-19 Salts of aromatic sulphonic acids

Publications (2)

Publication Number Publication Date
NO995770L true NO995770L (en) 1999-11-25
NO995770D0 NO995770D0 (en) 1999-11-25

Family

ID=8228372

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995770A NO995770D0 (en) 1997-05-26 1999-11-25 Salts of aromatic sulfonic acids

Country Status (12)

Country Link
EP (1) EP0984968A1 (en)
JP (1) JP2001526702A (en)
KR (1) KR20010012985A (en)
CN (1) CN1257504A (en)
AU (1) AU7767598A (en)
BR (1) BR9809162A (en)
CA (1) CA2290070A1 (en)
HU (1) HUP0002106A3 (en)
NO (1) NO995770D0 (en)
PL (1) PL337027A1 (en)
TR (1) TR199902727T2 (en)
WO (1) WO1998054186A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5067998B2 (en) 2001-10-30 2012-11-07 ノバルティス アーゲー Depot formulation of iloperidone and star polymer
HRP20020440B1 (en) 2002-05-21 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
HRP20020452A2 (en) 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
MX2007004485A (en) * 2004-10-15 2007-06-13 Organon Nv Treatment of bipolar disorders and associated symptoms.
TW201113018A (en) 2009-06-24 2011-04-16 Organon Nv Injectable formulations containing asenapine and method of treatment using same
ITMI20110734A1 (en) 2011-05-02 2012-11-03 Olon Spa CRYSTALLINE ASENAPINE SALTS
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2524921A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
MX2019007391A (en) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine.
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (en) * 1976-05-24 1977-11-28 Akzo Nv NEW TETRACYCLICAL DERIVATIVES.

Also Published As

Publication number Publication date
PL337027A1 (en) 2000-07-31
HUP0002106A2 (en) 2000-11-28
NO995770D0 (en) 1999-11-25
AU7767598A (en) 1998-12-30
WO1998054186A1 (en) 1998-12-03
HUP0002106A3 (en) 2001-11-28
BR9809162A (en) 2000-08-01
KR20010012985A (en) 2001-02-26
JP2001526702A (en) 2001-12-18
EP0984968A1 (en) 2000-03-15
CN1257504A (en) 2000-06-21
TR199902727T2 (en) 2000-07-21
CA2290070A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
NO995770L (en) Salts of aromatic sulfonic acids
CA2268886A1 (en) Aminothiophenecarboxamides
AU3260399A (en) Phenylalanine derivatives as inhibitors of alpha4 integrins
FI973879A0 (en) Thienyl, furyl, pyrrolyl and biphenyl sulfonamides and derivatives
GR3023174T3 (en) Substituted heterocyclic carboxylic acid amides, their preparation, and their use as medicaments.
BG102078A (en) (r)-(z)-1-azabicyclo[2.2.1]heptane-3-on, o-[3-(ethoxyphenyl)-2-propynyl]oxime maleate as a pharmacological formulation
DE69430465D1 (en) Inhibition of uterine fibrosis
AU8154794A (en) Methods of inhibiting seborrhea and acne
AU8156194A (en) Methods of inhibiting dysfunctional uterine bleeding
NO983864L (en) Morphine and diamorphine salts of anionic, non-narcotic analgesics of the substituted carboxyl type
EP0800828A4 (en) Transmucosal preparation
NO20003784L (en) Process for the preparation of enansiomerically pure cycloalkanoindolecarboxylic acid and azaindolecarboxylic acids and pyrimido 1,2a indolecarboxylic acids and derivatives thereof
CO4910113A1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS, BASED ON QUINU- PRISTINE AND DALPHOPRISTINE AND THEIR PREPARATION
EP1074264A4 (en) Neovascularization inhibitors
ZA953500B (en) Methods for treating neurofibromatosis
NO944920D0 (en) Procedure for inhibiting hirsutism and alopecia in women
HU9601527D0 (en) New peptid-andehyde derivatives of anticoagulant activity
ES8402818A1 (en) Pyrrole compounds as anti-inflammatory and analgesic agents.
PL324086A1 (en) Antagonists of calcium passages
TW343973B (en) Morphinan derivative and medical use
TH33723A (en)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application